Can we select NSCLC patients for immune checkpoint therapy?

17 / 38

Tumor mutational burden
Rizvi – JCO 2018
Challenges: Tournaround time, Threshold of TMB, Panel for testing, Tumor heterogeneity, Cost
MSK-IMPACT Trial. N=240 NSCLC
N=49.r=0.86, p<0.001